- Home
- ESPR vs LFMD Comparison
ESPR vs LFMD Comparison
Compare ESPR & LFMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- LFMD
- Stock Information
- Founded
- ESPR 2008
- LFMD 1994
- Country
- ESPR United States
- LFMD United States
- Employees
- ESPR N/A
- LFMD N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- LFMD Medical/Nursing Services
- Sector
- ESPR Health Care
- LFMD Health Care
- Exchange
- ESPR Nasdaq
- LFMD Nasdaq
- Market Cap
- ESPR 305.0M
- LFMD N/A
- IPO Year
- ESPR 2013
- LFMD N/A
- Fundamental
- Price
- ESPR $0.89
- LFMD $8.16
- Analyst Decision
- ESPR Buy
- LFMD Strong Buy
- Analyst Count
- ESPR 7
- LFMD 6
- Target Price
- ESPR $5.93
- LFMD $11.17
- AVG Volume (30 Days)
- ESPR 5.7M
- LFMD 2.1M
- Earning Date
- ESPR 05-06-2025
- LFMD 05-06-2025
- Dividend Yield
- ESPR N/A
- LFMD N/A
- EPS Growth
- ESPR N/A
- LFMD N/A
- EPS
- ESPR N/A
- LFMD N/A
- Revenue
- ESPR $259,574,000.00
- LFMD $234,007,330.00
- Revenue This Year
- ESPR $5.70
- LFMD $29.08
- Revenue Next Year
- ESPR N/A
- LFMD $18.81
- P/E Ratio
- ESPR N/A
- LFMD N/A
- Revenue Growth
- ESPR 12.99
- LFMD 43.07
- 52 Week Low
- ESPR $0.82
- LFMD $3.99
- 52 Week High
- ESPR $3.94
- LFMD $10.70
- Technical
- Relative Strength Index (RSI)
- ESPR 36.95
- LFMD 68.73
- Support Level
- ESPR $0.93
- LFMD $7.11
- Resistance Level
- ESPR $1.11
- LFMD $8.54
- Average True Range (ATR)
- ESPR 0.10
- LFMD 0.57
- MACD
- ESPR 0.02
- LFMD 0.20
- Stochastic Oscillator
- ESPR 25.10
- LFMD 84.99
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.